Hata Yosuke, Iida Osamu, Okamoto Shin, Ishihara Takayuki, Nanto Kiyonori, Tsujimura Takuya, Higashino Naoko, Toyoshima Taku, Nakao Sho, Ito Eisaku, Ohki Takao, Mano Toshiaki
Cardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Division of Cardiology, Osaka Police Hospital Osaka Japan.
Circ Rep. 2024 Jul 2;6(8):349-352. doi: 10.1253/circrep.CR-24-0052. eCollection 2024 Aug 9.
Cilostazol has reported effectiveness for preventing aspiration pneumonia in patients with ischemic stroke, but whether it is similarly beneficial for patients with chronic limb-threatening ischemia (CLTI) is unclear.
This retrospective single-center study enrolled 1,368 CLTI patients treated with endovascular therapy (EVT). In the multivariate analysis, predictors for aspiration pneumonia were age (hazard ratio [HR] 1.06 [95% confidence interval (CI) 1.03-1.10]), non-ambulatory status (HR 2.54 [95% CI 1.38-4.65]), the Geriatric Nutritional Risk Index (HR 0.97 [95% CI 0.95-0.99]), and cilostazol (HR 0.37 [95% CI 0.16-0.87]).
Cilostazol administration reduced the risk of aspiration pneumonia in patients with CLTI undergoing EVT.
已报道西洛他唑对预防缺血性中风患者的吸入性肺炎有效，但对于慢性肢体威胁性缺血（CLTI）患者是否同样有益尚不清楚。
这项回顾性单中心研究纳入了1368例接受血管内治疗（EVT）的CLTI患者。在多变量分析中，吸入性肺炎的预测因素包括年龄（风险比[HR]1.06[95%置信区间（CI）1.03 - 1.10]）、非步行状态（HR 2.54[95%CI 1.38 - 4.65]）、老年营养风险指数（HR 0.97[95%CI 0.95 - 0.99]）和西洛他唑（HR 0.37[95%CI 0.16 - 0.87]）。
在接受EVT的CLTI患者中，使用西洛他唑可降低吸入性肺炎的风险。
